3[1]Kinlay S, Selwyn AP, Delagrange D, et al. Biological mechanisms for the clinical success of lipid - lowering in coronary artery disease and the use of surrogate end points [ J ]. Curr Opin Lipidol, 1996,7: 389 - 397.
4[2]Eugene Braunward MD, Chair Joel Kupersmith MD, Elliott M Antman MD, et al. ACC / AHA 2002 Guideline Update for Management of Patients with Unstable Angina and Non - ST - Segment Elevation Myocardial Infarction[J].J Am Coll Cardiol, 2002,40: 366 - 374.
5[4]Kinlay S, Schwartz GG, Olsson AG, et al. Biological mechanism for the clinical success of lipid - lowering in coronary arthry disease and the use of surrogate endpoints [J]. Curr Opin Lipidol, 1996,7 . 389 - 397.
6[5]Bybee KY, Wright RS, Kopecky SL. Effect of early statin therapy after actue coronary syndromes :a concise review of the recent data[ J ]. Cardiol Rew,2002,10(5) :301 - 305.
7[6]Mosca L,Biviano A. Lipid - lowering therapies in the management of acute coronary syndromes [ J ]. Curr Cardiol Rep, 2002,4 (4): 320 - 326.
8[7]Water DD. Early pharmacologic intervention and plaque stability in acute coronary syndromes [J]. Am J Cardiol, 2001,88 (8A) :30K -36K.
9[8]Osborne JA, Lento PH, Siegfried, et al. Cardiovascular effects of acute hypercholesterolemia in rabbits. Reversal with lovastatin treatment [ J ].J Clin Invest, 1989,83 (2): 456 - 473.
10[9]Laufs U, La Fata V, Liao JK. Inhibition of HMG - CoA reductase blocks hypoxia -mediated down regulation of endothelial nitric oxide synthase [ J].J Biol Chem, 1997,272(50) :31 725 - 31 729.
2Cannon CP, Ibraunwald E, Mc Cabe C, et al. Intensive versue moderate lipid lowering with statins after acute coronayr syndormes [ J]. N Engl J Mod, 2004, 350 (15) :1495-1504.
